Next 10 |
home / stock / lbtsf / lbtsf news
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...
2024-03-11 05:53:32 ET Eli Lilly ( NYSE: LLY ) on Sunday reported robust efficacy data from a study for its atopic dermatitis drug, lebrikizumab.... Read the full article on Seeking Alpha For further details see: Eli Lilly eczema drug shows robust efficacy in peo...
2024-02-19 17:55:04 ET Almirall, S.A. (LBTSF) Q4 2023 Earnings Conference Call February 19, 2024, 04:00 AM ET Company Participants Pablo Divasson - Director, IR and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - CFO Karl Ziegelba...
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...
The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223 ALM223 has the potential to rebalance the immune system in several autoimmune diseases 1,2 Almirall S.A. (BME: ALM ) , a global pharmaceutical compa...
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront a...
Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity, selectively inhibiting its downstream signalling 1-4 Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription Lebrikizumab demons...
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases Almirall S.A. (BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, and Absci Corpo...
2023-11-11 00:59:06 ET Almirall, S.A. (LBTSF) Q3 2023 Earnings Conference Call November 9, 2023, 4:00 AM ET Company Participants Pablo Divasson - Director, Investor Relations and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - Chief F...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...